Plasma is a better source of tumor-derived circulating cell-free DNA than serum for the detection of EGFR alterations in lung tumor patients.

[1]  Koichi Goto,et al.  Epidermal Growth Factor Receptor Mutation Status in Circulating Free DNA in Serum: From IPASS, a Phase III Study of Gefitinib or Carboplatin/Paclitaxel in Non-small Cell Lung Cancer , 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[2]  Klaus Pantel,et al.  Cell-free nucleic acids as biomarkers in cancer patients , 2011, Nature Reviews Cancer.

[3]  E. Felip,et al.  Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. , 2012, The Lancet. Oncology.

[4]  Kikuya Kato,et al.  Quantitative Detection of EGFR Mutations in Circulating Tumor DNA Derived from Lung Adenocarcinomas , 2011, Clinical Cancer Research.

[5]  Hakan Akca,et al.  Utility of serum DNA and pyrosequencing for the detection of EGFR mutations in non-small cell lung cancer. , 2013, Cancer genetics.

[6]  Chan Kwon Park,et al.  Detection and comparison of EGFR mutations in matched tumor tissues, cell blocks, pleural effusions, and sera from patients with NSCLC with malignant pleural effusion, by PNA clamping and direct sequencing. , 2013, Lung cancer.

[7]  P Mandel,et al.  Les acides nucleiques du plasma sanguin chez l' homme , 1948 .

[8]  S. Kimura,et al.  Application of a Highly Sensitive Detection System for Epidermal Growth Factor Receptor Mutations in Plasma DNA , 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[9]  G. Hampton,et al.  Evaluation of Circulating Tumor Cells and Circulating Tumor DNA in Non–Small Cell Lung Cancer: Association with Clinical Endpoints in a Phase II Clinical Trial of Pertuzumab and Erlotinib , 2011, Clinical Cancer Research.

[10]  Kunihiko Kobayashi,et al.  Clinical significance of circulating tumor cells and free DNA in non-small cell lung cancer. , 2012, Anticancer research.

[11]  F. Mouliere,et al.  Circulating cell free DNA: Preanalytical considerations. , 2013, Clinica chimica acta; international journal of clinical chemistry.